Medical News

RSS

Concord Medical announces joint venture with Chang'An Hospital for operation of cancer treatment facilities

Concord Medical Services Holdings Limited, the operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that effective as of July 1, 2010 it has entered into a joint venture with Chang'An Hospital for the operation of Chang'An Hospital's cancer treatment facilities by acquiring a 52% equity interest in Xi'an Wan Jie Hua Xiang Medical Technology Development Limited.

12 Jul 2010

UHC awards a 3-year single-source agreement to Ascent

The University HealthSystem Consortium today announced that it has awarded a 3-year single-source agreement to Ascent, a leader in health care resource sustainability. The agreement, which has 2 optional 1-year renewal periods, became effective on July 1, 2010. Under the contract, Ascent will offer single-use device reprocessing programs to UHC's 107 academic medical centers and 233 affiliated hospitals.

12 Jul 2010

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

12 Jul 2010

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that a manuscript based on a study of Clarient InsightDx Mammostrat, a test used to classify the risk of recurrence of breast cancer following surgery and chemotherapy, will be published in an upcoming edition of Breast Cancer Research, a prominent peer-reviewed medical journal.

12 Jul 2010

FDA grants Catheter Connections 510(k) clearance for DualCap disinfecting product

Catheter Connections, Inc., a manufacturer of innovative vascular access and infection control products, today announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market its DualCap™ product. DualCap is the only device that nests two disinfecting caps together - for both IV access points, the needleless injection site (NIS) and the male luer at the end of the IV tubing. Previously overlooked as a route of microbial colonization, Catheter Connections has developed the first disinfecting cap for the male luer.

12 Jul 2010

Researchers explore range of potential new fuel sources in nature

On the long and difficult road toward a carbon-neutral source of transportation fuels, the U.S. Department of Energy is pursuing a diversified approach. This effort involves exploring a range of potential new fuel sources in nature: from plants that may serve as cellulosic feedstocks-fast-growing trees and perennial grasses on land-to oil-producing organisms in aquatic and other environments, such as algae and bacteria.

12 Jul 2010

Alzheimer's Association launches Internet and phone-based clinical trial matching service

The Alzheimer's Association announced today the launch of Alzheimer's Association TrialMatch(TM), a confidential and free interactive tool that provides comprehensive clinical trial information and an individualized trial matching service for people with Alzheimer's disease and related dementias. The Internet (www.alz.org/trialmatch) and phone-based (800-272-3900) service debuted during the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (AAICAD 2010) in Honolulu, HI.

12 Jul 2010

Higher negative emotional traits linked to fewer risks taken by bodies managed by directors

"We have analysed emotional traits of low intensity. In this context, the higher the negative emotional traits are, the fewer risks taken by the bodies managed by the directors", Juan Bautista Delgado Garc-a, co-author of the study and researcher at UBU declares to SINC.

12 Jul 2010

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

Medivir announced today 24-week end-of-treatment interim results from the 5-arm phase 2b response guided PILLAR study in 386 treatment-naïve patients with hepatitis C virus (HCV) genotype-1 (TMC435-C205).

12 Jul 2010

New website presenting latest in Alzheimer's disease research unveiled at AAICAD 2010

A new website showcasing the latest in Alzheimer's disease research and science - www.alz.org/research - is being unveiled at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 in Honolulu.

12 Jul 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

Irvine Scientific, a member of JX Holdings group, announced today the opening of a new Industrial Cell Culture media production facility in Tokyo, Japan. The new facility, located in Saitama prefecture, will manufacture the Company's cell culture media for production of biopharmaceuticals, vaccines, monoclonal antibodies and other media's used in pharmaceuticals, medicines, and research. The facility is being commissioned and validated as completely animal component free manufacturing facility.

12 Jul 2010

New approach of screening drugs that encourage stem cells to repair damaged tissue

Professor Fiona Watt will today (12 July) give the Anne McLaren Memorial Lecture at the UK National Stem Cell Network annual science meeting and will detail a new approach to screening for drugs that target stem cells. To begin with, this is being developed for adult skin stem cells, giving hope for new drugs to promote wound healing and aid the use of stem cells to, for example, treat severe burns. This technique can also be applied to a wide range of stem cells, opening up the possibilities for harnessing stem cells in regenerative medicine.

12 Jul 2010

BCAN to celebrate first annual Bladder Cancer Awareness Day

The Bladder Cancer Advocacy Network will celebrate the first annual Bladder Cancer Awareness Day on Saturday, July 17 with more than two dozen volunteer-led events nationwide. In addition to raising public awareness about the risks and signs of bladder cancer, the events will serve as a forum for bladder cancer patients, survivors and their caregivers to meet and share their stories.

12 Jul 2010

Counseling parents of infants about when to stop using bottle can reduce tooth decay, obesity and iron deficiency

Family doctors and pediatricians can influence when parents wean their children from the bottle, thereby helping to reduce tooth decay, obesity and iron deficiency, according to a new study by researchers at St. Michael's Hospital and The Hospital for Sick Children (SickKids).

12 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

KAEL-GemVax, a leading oncology vaccine company, today announced, through its subsidiary GemVax A.S, encouraging interim progress from the UK-based Phase III TeloVac study of its anti-telomerase therapeutic cancer vaccine GV1001 in pancreatic cancer. The company also strongly believes GV1001 has major "blockbuster" potential as a universal therapeutic cancer vaccine and is developing a strong pipeline for other indications, including lung and liver cancer and melanoma.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

Statement showing results of three-day meeting between Identa and U.S. representative issued

IDenta Corp. CEO Yaacov Shoham today issued a statement on the results of the three day meeting between executives of Identa Corp and the new United States representative for marketing of Identa products.

12 Jul 2010

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Biogen Idec and Swedish Orphan Biovitrum AB today announced results from a Phase 1/2a open-label, dose-escalation, safety and pharmacokinetic study of the companies' long-lasting, fully-recombinant factor IX Fc fusion protein (rFIXFc) in hemophilia B patients. The data, which were presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010, showed that rFIXFc was well tolerated and demonstrated an approximately three-fold increase in half-life compared to historical data for existing therapies.

12 Jul 2010

Addition of fat to mouse stem cells push them to develop into subcutaneous or visceral fat storage cells

New research being presented today (12 July) at the UK National Stem Cell Network Annual Science Meeting in Nottingham shows that adding fat to mouse stem cells grown in the lab affects their response to the signals that push them to develop into one or other of the main types of fat storage cells - subcutaneous (under the skin) or visceral (around the organs).

12 Jul 2010

Medical News

Concord Medical announces joint venture with Chang'An Hospital for operation of cancer treatment facilities

UHC awards a 3-year single-source agreement to Ascent

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Manuscript based on study of Clarient InsightDx Mammostrat to be published in Breast Cancer Research

FDA grants Catheter Connections 510(k) clearance for DualCap disinfecting product

Researchers explore range of potential new fuel sources in nature

Alzheimer's Association launches Internet and phone-based clinical trial matching service

Higher negative emotional traits linked to fewer risks taken by bodies managed by directors

Medivir reports 24-week interim Phase 2b results of TMC435 in treatment-naïve patients with HCV genotype-1

New website presenting latest in Alzheimer's disease research unveiled at AAICAD 2010

Irvine Scientific opens new Industrial Cell Culture media production facility in Tokyo, Japan

New approach of screening drugs that encourage stem cells to repair damaged tissue

BCAN to celebrate first annual Bladder Cancer Awareness Day

Counseling parents of infants about when to stop using bottle can reduce tooth decay, obesity and iron deficiency

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Interim progress from Phase III TeloVac study of GV1001 vaccine announced

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Statement showing results of three-day meeting between Identa and U.S. representative issued

Biogen Idec, Swedish Orphan Biovitrum present results from rFIXFc Phase 1/2a study in hemophilia B

Addition of fat to mouse stem cells push them to develop into subcutaneous or visceral fat storage cells

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News